Publicação
Clinical management of thromboembolic events arising from complications of COVID-19: integrative review
| Resumo: | Objective: to identify how the clinical management of patients infected with COVID-19 who present pulmonary thromboembolism and/or venous thromboembolism occurs. Method: This is an integrative review, carried out by searching for articles in the VHL, LILACS, MEDLINE, CINAHL AND SCOPUS databases, with a temporal delimitation from November 2019 to March 2021. Results: 24 articles were included. Diagnosis occurs through D-dimer and fibrinogen. For drug therapy, low molecular weight heparin (LMWH) is administered, 30 mg/12h in 12h for prophylactic anticoagulation, staggered doses of LMWH with enoxaparin, 0.5 mg/kg twice a day for anticoagulation therapy and rivoxaban 10mg/day for post-discharge anticoagulation. Conclusion: Clinical management of TEP and VTE occurs through increased D-dimer or fibrinogen, with TEP confirmed by pulmonary angiography. For anticoagulation, LMWH is mostly used. |
|---|---|
| Autores principais: | Bispo, Laura Dayane Gois |
| Outros Autores: | Machado, Natan Martins; Paula, Caio Lopes Pinheiro de; Oliveira, Jussiely Cunha; Santos, Ingrid Melo; Pinheiro, Fernanda Gomes de Magalhães Soares |
| Assunto: | Tromboembolismo venoso Embolia pulmonar COVID-19 Gestión clínica. Venous thromboembolism Pulmonary embolism COVID-19 Clinical management. Tromboembolia venosa Embolia pulmonar COVID-19 Gerenciamento clínico. |
| Ano: | 2021 |
| País: | Brasil |
| Tipo de documento: | artigo |
| Tipo de acesso: | unknown |
| Instituição associada: | IBICT |
| Idioma: | português |
| Origem: | Oasisbr |
| Resumo: | Objective: to identify how the clinical management of patients infected with COVID-19 who present pulmonary thromboembolism and/or venous thromboembolism occurs. Method: This is an integrative review, carried out by searching for articles in the VHL, LILACS, MEDLINE, CINAHL AND SCOPUS databases, with a temporal delimitation from November 2019 to March 2021. Results: 24 articles were included. Diagnosis occurs through D-dimer and fibrinogen. For drug therapy, low molecular weight heparin (LMWH) is administered, 30 mg/12h in 12h for prophylactic anticoagulation, staggered doses of LMWH with enoxaparin, 0.5 mg/kg twice a day for anticoagulation therapy and rivoxaban 10mg/day for post-discharge anticoagulation. Conclusion: Clinical management of TEP and VTE occurs through increased D-dimer or fibrinogen, with TEP confirmed by pulmonary angiography. For anticoagulation, LMWH is mostly used. |
|---|
Atividades financiadas
Não foram encontrados projetos financiados.